Novel CD20 monoclonal antibodies for lymphoma therapy

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Cang, Shundong ^a   Mukhi, Nikhil ^b   Wang, Kemeng ^b   Liu, Delong ^b  

^a Peoples Hospital   (China)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN G1; OBINUTUZUMAB; OCARATUZUMAB; OCRELIZUMAB; OFATUMUMAB; PREDNISONE; PRO 131921; RITUXIMAB; UNCLASSIFIED DRUG; VELTUZUMAB; VINCRISTINE;

ASTHENIA; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHEMOTHERAPY INDUCED ANEMIA; CHROMOSOME 17P; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; FOLLOW UP; GENOTYPE; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; INFECTION; INFUSION RELATED REACTION; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREMEDICATION; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 84867236304     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-64     Document Type: Review

References (116)

1. Rituximab in the treatment of diffuse large B-cell lymphomas. Coiffier B, Semin Oncol 2002 29 1 Suppl 2 30 35 12571808 (Pubitemid 34171792)
2. Rituximab in diffuse large B-cell lymphoma. Coiffier B, Clin Adv Hematol Oncol 2004 2 3 156 157 16166943
3. Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma. Coiffier B, Nature clinical practice Oncology 2006 3 11 594 595 17080173 (Pubitemid 44669710)
4. Rituximab therapy in malignant lymphoma. Coiffier B, Oncogene 2007 26 25 3603 3613 10.1038/sj.onc.1210376 17530014 (Pubitemid 46844778)
5. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. N Engl J Med 2002 346 4 235 242 10.1056/NEJMoa011795 11807147 (Pubitemid 34438862)
6. R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma. Mishima Y, Terui Y, Yokoyama M, Nishimura N, Sakajiri S, Ueda K, Kuboki Y, Nakano K, Suzuki K, Nara E, et al. Experimental Hematology & Oncology 2012 1 1 30 10.1186/2162-3619-1-30 23082251
7. The future of anti-CD20 monoclonal antibodies: are we making progress? Alduaij W, Illidge TM, Blood 2011 117 11 2993 3001 10.1182/blood-2010-07-298356 21209380
8. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, et al. Blood 2011 117 17 4519 4529 10.1182/blood-2010-07-296913 21378274
9. CD20: a regulator of cell-cycle progression of B lymphocytes. Tedder TF, Engel P, Immunol Today 1994 15 9 450 454 10.1016/0167-5699(94)90276-3 7524522 (Pubitemid 24272191)
10. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Goldenberg DM, Morschhauser F, Wegener WA, Leuk Lymphoma 2010 51 5 747 755 10.3109/10428191003672123 20214444
11. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Uchiyama S, Suzuki Y, Otake K, Yokoyama M, Ohta M, Aikawa S, Komatsu M, Sawada T, Kagami Y, Morishima Y, et al. Cancer Sci 2010 101 1 201 209 10.1111/j.1349-7006.2009.01392.x 19930155
12. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. Robak T, Robak E, BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 2011 25 1 13 25 10.2165/11539590-000000000- 00000
13. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC, Blood 2010 116 19 3705 3714 10.1182/blood-2010-04-001230 20610811
14. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, Huang P, Cragg MS, Illidge TM, Blood 2012 119 15 3523 3533 10.1182/blood-2011-12-395541 22354003
15. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Czuczman MS, Gregory SA, Leukemia & lymphoma 2010 51 6 983 994 10.3109/10428191003717746 23082329
16. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL, Figgitt DP, Drugs 2003 63 8 803 843 10.2165/00003495-200363080-00005 12662126 (Pubitemid 36432084)
17. Aggressive lymphoma: improving treatment outcome with rituximab. Coiffier B, Pfreundschuh M, Stahel R, Vose J, Zinzani PL, Anticancer Drugs 2002 13 Suppl 2 43 50 12710590
18. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani P, et al. Lancet Oncol 2006 7 5 379 391 10.1016/S1470-2045(06)70664-7 16648042
19. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A, J Nucl Med 2009 50 11 1837 1843 10.2967/jnumed.109.067587 19837764
20. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, et al. Ann Oncol 2009 20 4 709 714 10.1093/annonc/mdn692 19150940
21. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Friedberg JW, Fisher RI, Expert Rev Anticancer Ther 2004 4 1 18 26 10.1586/14737140.4.1.18 14748653 (Pubitemid 38208483)
22. Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. Buchegger F, Antonescu C, Helg C, Kosinski M, Prior JO, Delaloye AB, Press OW, Ketterer N, J Nucl Med 2011 52 6 896 900 10.2967/jnumed.111.087460 21571800
23. Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma. Corazzelli G, Frigeri F, Marcacci G, Capobianco G, Arcamone M, Becchimanzi C, Russo F, Pinto A, ASCO Meeting Abstracts 2009 27 15S 8579
24. Rituximab, gemcitabine and oxaliplatin (R-GEMOX): An effective regimen for relapsed and refractory B-cell lymphoma. El Gnaoui T, Dupuis J, Belhadj K, Rahmouni A, Copie-Bergman C, Gaillard I, Divine M, Tabah-Fisch IM, Reyes F, Haioun C, ASCO Meeting Abstracts 2006 24 18 7562
25. R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). Federico M, Luminari S, Dondi A, Sacchi S, Franco V, Pileri S, Lombardo M, Rossi G, Arcaini L, Chisesi T, et al. ASCO Meeting Abstracts 2012 30 15 8006
26. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Recher C, Coiffier B, Haioun C, Molina TJ, Ferme C, Casasnovas O, Thieblemont C, Bosly A, Laurent G, Morschhauser F, et al. Lancet 2011 378 9806 1858 1867 10.1016/S0140-6736(11)61040-4 22118442
27. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L, Investigational new drugs 2012 30 3 1232 1240 10.1007/s10637-011-9737-y 21922186
28. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. Rummel MJ, Niederle N, Maschmeyer G, Banat AG, von Gruenhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, et al. ASCO Meeting Abstracts 2012 30 18 3
29. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Tilly H, Morschhauser F, Salles G, Casasnovas RO, Feugier P, Molina TJ, Jardin F, Terriou L, Haioun C, Coiffier B, Leukemia 2012 26 http://www.ncbi.nlm.nih.gov/pubmed/22733106
30. Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). Tsimberidou AM, Wierda WG, Badoux X, Wen S, Plunkett W, O'Brien SM, Kipps TJ, Jones JA, Kantarjian H, Keating MJ, ASCO Meeting Abstracts 2010 28 15 6521
31. Phase I/II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL). Tsimberidou AM, Wierda WG, Plunkett WK, O'Brien S, Lerner S, Smith SC, Kantarjian HM, Keating MJ, ASCO Meeting Abstracts 2009 27 15S 7031
32. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, Nowakowski GS, Zent CS, Leuk Lymphoma 2012:http://www.ncbi.nlm.nih.gov/pubmed/22475085 2012
33. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, et al. Blood 2008 111 3 1094 1100 18003886 (Pubitemid 351213387)
34. Therapy of elderly/comorbid patients with chronic lymphocytic leukemia. Smolej L, Curr Pharm Des 2012 http://www.ncbi.nlm.nih.gov/pubmed/22591390
35. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, et al. Blood 2011 117 24 6450 6458 10.1182/blood-2010-12-323980 21498674
36. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, et al. J Clin Oncol 2010 28 10 1749 1755 10.1200/JCO.2009.25.3187 20194866
37. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A, Hx CDSI, Blood 2011 118 19 5126 5129 10.1182/blood-2011-04-348656 21856867
38. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS, Br J Haematol 2012 156 4 490 498 10.1111/j.1365-2141.2011.08966.x 22150234
39. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Cheson BD, J Clin Oncol 2010 28 21 3525 3530 10.1200/JCO.2010.27.9836 20458041
40. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, et al. Blood 2012 119 16 3698 3704 10.1182/blood-2011-09-378323 22389254
41. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Strange C, et al. Br J Haematol 2012 157 4 438 445 10.1111/j.1365-2141.2012.09086.x 22409295
42. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, et al. J Clin Oncol 2009 27 20 3346 3353 10.1200/JCO.2008.19.9117 19451441
43. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Morschhauser F, Marlton P, Vitolo U, Linden O, Seymour JF, Crump M, Coiffier B, Foa R, Wassner E, Burger HU, et al. Ann Oncol 2010 21 9 1870 1876 10.1093/annonc/mdq027 20157180
44. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM, Clin Cancer Res 2004 10 8 2868 2878 10.1158/1078-0432.CCR-03-0493 15102696 (Pubitemid 38509167)
45. Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP). Saleh MN, Liebman H, Bernstein ZP, Negrea OG, Bussel JB, Onyegbula AC, Farber CM, Abassi R, Cosgriff TM, Pennington K, et al. ASH Annual Meeting Abstracts 2009 114 22 1322
46. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, Maruyama D, Suzuki T, Mori M, Kasai M, et al. Cancer Sci 2011 102 2 432 438 10.1111/j.1349-7006.2010. 01809.x 21205069
47. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA, et al. Clin Cancer Res 2012 18 5 1395 1403 10.1158/1078-0432.CCR-11-0850 22223529
48. Efficacy of ocaratuzumab (AME-133v) in relapsed follicular lymphoma patients refractory to prior rituximab. Wayne JL, Ganjoo KN, Pohlman BL, De Vos S, Flinn IW, Dang NH, Mapara MY, Smith MR, O'Reilly AM, Marulappa SY, et al. ASCO Meeting Abstracts 2012 30 15 8081
49. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, et al. Blood 2012 119 22 5126 5132 10.1182/blood-2012- 01-404368 22431570
50. Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000). Carlile D, Meneses-Lorente G, Wassner-Fritsch E, Hourcade-Potelleret F, Wenger MK, Cartron G, Vitolo U, Radford J, Davies A, Morschhauser F, ASH Annual Meeting Abstracts 2011 118 21 3704
51. A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics. Friedberg JW, Vose J, Kahl BS, Brunvand M, Goy A, Kasamon Y, Brington B, Li J, Ho W, Cheson BD, ASH Annual Meeting Abstracts 2009 114 3472
52. Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Kahl BS, Cheson BD, Friedberg JW, Clin Adv Hematol Oncol 2010 8 5 1 16 21491667
53. CD20-targeted therapy: the next generation of antibodies. van Meerten T, Hagenbeek A, Seminars in hematology 2010 47 2 199 210 10.1053/j.seminhematol. 2010.01.007 20350667
54. GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Mediates Superior Efficacy in a Variety of NHL Xenograft Models in Comparison to Rituximab. Friess T, Gerdes C, Nopora A, Patre M, Preiss S, van Puijenbroek E, Schuell C, Bauer S, Umana P, Klein C, ASH Annual Meeting Abstracts 2007 110 11 2338
55. Differential Regulation Patterns of Anti-CD20 Antibodies GA101 and Rituximab in Mantle Cell Lymphoma. Heinrich D, Weinkauf M, Hutter G, Decheva K, Zimmermann Y, Hiddemann W, Dreyling MH, ASH Annual Meeting Abstracts 2010 116 21 1839
56. Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263. Herting F, Bader S, Umana P, Klein C, ASH Annual Meeting Abstracts 2010 116 21 3915
57. GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo. Umana P, Ekkehard M, Peter B, Gabriele K, Ursula P, Suter T, Grau R, Schmidt C, Herter S, Gerdes C, et al. ASH Annual Meeting Abstracts 2007 110 11 2348
58. Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice. Dalle S, Reslan L, Manquat SB, Herting F, Klein C, Umana P, Dumontet C, ASH Annual Meeting Abstracts 2008 112 11 1585
59. Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells. Ysebaert L, Laprevotte E, Klein C, Laurent G, Fournie J-J, Quillet-Mary A, ASH Annual Meeting Abstracts 2010 116 21 2459
60. Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999). Salles GA, Morschhauser F, Thieblemont C, Solal-Celigny P, Lamy T, Tilly H, Feugier P, Le Gouill S, Gyan E, Bouabdallah R, et al. ASH Annual Meeting Abstracts 2011 118 21 268
61. Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999). Meneses-Lorente G, Carlile D, Birkett J, Wenger MK, Cartron G, Morschhauser F, Salles GA, ASH Annual Meeting Abstracts 2010 116 21 1833
62. Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study. Sehn LH, Goy A, Offner FC, Martinelli G, Friedberg J, Lasserre SF, Fine G, Press OW, ASH Annual Meeting Abstracts 2011 118 21 269
63. Histone deacetylase inhibitors as anti-neoplastic agents. Batty N, Malouf G, Issa J, Cancer Lett 2009 280 192 200 10.1016/j.canlet.2009.03.013 19345475
64. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). Brown JR, Sharman JP, Harb WA, Kelly KR, Schreeder MT, Sweetenham JW, Barr PM, Foran JM, Gabrilove JL, Kipps TJ, et al. ASCO Meeting Abstracts 2012 30 15 8032
65. The clinical potential of microRNAs. Budhu A, Ji J, Wang X, Journal of Hematology & Oncology 2010 3 1 37 10.1186/1756-8722-3-37 23065527
66. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Sharman JP, Flinn IW, Grant BW, Heerema NA, Johnson AJ, et al. ASCO Meeting Abstracts 2012 30 15 6507
67. Lenalidomide for the treatment of B-cell malignancies. Chanan-Khan A, Cheson B, J Clin Oncol 2008 26 1544 1552 10.1200/JCO.2007.14.5367 18285605
68. Bendamustine: more ammunition in the battle against mantle cell lymphoma. Chang JE, Kahl BS, Leuk Lymphoma 2012 53 7 1249 1250 10.3109/10428194.2011. 654342 22220986
69. Digitoxin and its analogs as novel cancer therapeutics. Elbaz H, Stueckle T, Tse W, Rojanasakul Y, Dinu C, Experimental Hematology & Oncology 2012 1 1 4 10.1186/2162-3619-1-4 23082251
70. Role of Wnt canonical pathway in hematological malignancies. Ge X, Wang X, Journal of Hematology & Oncology 2010 3 1 33 10.1186/1756-8722-3-33 23065527
71. New targets for lymphoma treatment. Johnson P, Ann Oncol 2008 19 4 56 59 17947222
72. Targeted therapy of lymphoma. Patrick J, Yuan R, Cavalli F, Thomas W, J Hematol Oncol 2010 3 45 10.1186/1756-8722-3-45 21092307
73. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Tan J, Cang S, Ma Y, Petrillo RL, Liu D, J Hematol Oncol 2010 3 5 10.1186/1756-8722-3-5 20132536
74. STAT proteins as novel targets for cancer drug discovery. Turkson J, Expert Opin Ther Targets 2004 8 5 409 422 10.1517/14728222.8.5.409 15469392 (Pubitemid 39359648)
75. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. Wu ZL, Song YQ, Shi YF, Zhu J, J Hematol Oncol 2011 4 1 31 10.1186/1756-8722-4-31 21806788
76. Novel targeted therapeutics: inhibitors of MDM2. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR, ALK and PARP. J Hematol Oncol 2011 4 16 10.1186/1756-8722-4- 16
77. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Adams J, Palombella V, Sausville E, Johnson J, Destree A, Lazarus D, Maas J, Pien C, Prakash S, Elliott P, Cancer Res 1999 59 2615 2622 10363983 (Pubitemid 29269108)
78. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Belch A, Kouroukis C, Crump M, Sehn L, Gascoyne R, Klasa R, Powers J, Wright J, Eisenhauer E, Ann Oncol 2007 18 116 121 16971665 (Pubitemid 46152510)
79. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Blum K, Johnson J, Niedzwiecki D, Canellos G, Cheson B, Bartlett N, Leuk Lymphoma 2007 48 1313 1319 10.1080/10428190701411458 17613759 (Pubitemid 47079358)
80. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, et al. Lancet Oncol 2011 12 8 773 784 10.1016/S1470-2045(11)70150-4 21724462
81. VcR-CVAD produces a high response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin Oncology Network. Kahl B, Chang J, Eickhoff J, Gilbert L, Rogers E, Werndli J, Huie M, McFarland T, Volk M, Blank J, et al. Blood 2008 112 Suppl 1 265
82. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Mendler J, Kelly J, Voci S, Marquis D, Rich L, Rossi R, Bernstein S, Jordan C, Liesveld J, Fisher R, et al. Ann Oncol 2008 19 1759 1764 10.1093/annonc/mdn365 18504251
83. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Mitsiades C, Mitsiades N, Hideshima T, Richardson P, Anderson K, Curr Drug Targets 2006 7 1341 1347 10.2174/138945006778559247 17073596 (Pubitemid 44509698)
84. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A, Borchmann P, Haematologica 2007 92 568 569 10.3324/haematol.10797 17488673 (Pubitemid 350144308)
85. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma-long-term results of a multicenter observation study. Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M, Leuk Lymphoma 2009 50 716 722 10.1080/10428190902856790 19347767
86. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Habermann T, Lossos I, Justice G, Vose J, Wiernik P, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, et al. Br J Haematol 2009 145 344 349 10.1111/j.1365-2141.2009. 07626.x 19245430
87. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Altman J, Platanias L, Curr Opin Hematol 2008 15 88 94 10.1097/MOH.0b013e3282f3deaa 18300753 (Pubitemid 351323147)
88. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, et al. J Clin Oncol 2009 27 3822 3829 10.1200/JCO.2008.20.7977 19581539
89. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Johnston P, Inwards D, Colgan J, LaPlant B, Kabat B, Habermann T, Micallef I, Porrata L, Ansell S, Reeder C, et al. Am J Hematol 2010 85 320 324 20229590
90. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Jundt F, Raetzel N, Muller C, Calkhoven C, Kley K, Mathas S, Lietz A, Leutz A, Dorken B, Blood 2005 106 1801 1807 10.1182/blood-2004-11-4513 15886325 (Pubitemid 41208597)
91. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Teachey D, Grupp S, Brown V, Br J Haematol 2009 145 569 580 10.1111/j.1365-2141.2009.07657.x 19344392
92. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. Witzig T, Geyer S, Ghobrial I, Inwards D, Fonseca R, Kurtin P, Ansell S, Luyun R, Flynn P, Morton R, et al. J Clin Oncol 2005 23 5347 5356 10.1200/JCO.2005.13.466 15983389 (Pubitemid 46206988)
93. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Yazbeck V, Buglio D, Georgakis G, Li Y, Iwado E, Romaguera J, Kondo S, Younes A, Exp Hematol 2008 36 443 450 10.1016/j.exphem.2007.12.008 18343280 (Pubitemid 351384743)
94. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Yee K, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, et al. Clin Cancer Res 2006 12 5165 5173 10.1158/1078-0432.CCR-06-0764 16951235 (Pubitemid 44453345)
95. STAT3: a critical transcription activator in angiogenesis. Chen Z, Han Z, Med Res Rev 2008 28 2 185 200 10.1002/med.20101 17457812 (Pubitemid 351281185)
96. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Ding B, Yu J, Yu R, Mendez L, Shaknovich R, Zhang Y, Cattoretti G, Ye B, Blood 2008 111 3 1515 1523 17951530 (Pubitemid 351213441)
97. The four types of Tregs in malignant lymphomas. Wang J, Ke XY, J Hematol Oncol 2011 4 50 10.1186/1756-8722-4-50 22151904
98. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C, Clin Cancer Res 2009 15 12 4038 4045 10.1158/1078-0432.CCR-08- 2808 19509168
99. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM, Clin Cancer Res 2011 17 20 6448 6458 10.1158/1078-0432.CCR-11-0485 22003072
100. Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, et al. J Clin Oncol 2012 30 22 2776 2782 10.1200/JCO.2011.39.4403 22753910
101. Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin's lymphoma (NCT00796731). Coiffier B, Morschhauser F, Dupuis J, Haioun C, Laine F, Houot R, Tilly H, Brehar O, Lambert JM, Fagniez N, et al. ASCO Meeting Abstracts 2012 30 15 8057
102. Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues. Schweizer A, Wohner M, Prescher H, Brossmer R, Nitschke L, Eur J Immunol 2012 2012 2012 http://www.ncbi.nlm.nih.gov/pubmed/22777817
103. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, et al. The lancet oncology 2012 13 4 403 411 10.1016/S1470-2045(11)70386-2 22357140
104. Anti-CD22 therapy in acute lymphoblastic leukaemia. Hoelzer D, The lancet oncology 2012 13 4 329 331 10.1016/S1470-2045(12)70010-4 22357139
105. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I, Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012 30 15 1822 1828 10.1200/JCO.2011.38.1756
106. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Ogura M, Hatake K, Ando K, Tobinai K, Tokushige K, Ono C, Ishibashi T, Vandendries E, Cancer science 2012 103 5 933 938 10.1111/j.1349-7006.2012.02241.x 22335424
107. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM, Molecular cancer therapeutics 2012 11 1 224 234 10.1158/1535-7163.MCT-11-0632 22039078
108. CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia. Ma H, Qazi S, Ozer Z, Gaynon P, Reaman GH, Uckun FM, British journal of haematology 2012 156 1 89 98 10.1111/j.1365-2141.2011.08901.x 22017452
109. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. de Vries JF, Zwaan CM, De Bie M, Voerman JS, den Boer ML, van Dongen JJ, van der Velden VH, Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2012 26 2 255 264 10.1038/leu.2011.206
110. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Chen WC, Sigal DS, Saven A, Paulson JC, Leukemia & lymphoma 2012 53 2 208 210 10.3109/10428194.2011.604755 23082329
111. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-betaII depletion. Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, Kreitman RJ, Peschel C, Pastan I, Meyer Zum Buschenfelde C, et al. Haematologica 2012 97 5 771 779 10.3324/haematol.2011.049155 22180432
112. Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Sikder MA, Friedberg JW, Curr Hematol Malig Rep 2008 3 4 187 193 10.1007/s11899-008-0027-5 20425465
113. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Gualberto A, Expert Opin Investig Drugs 2012 21 2 205 216 10.1517/13543784.2011.641532 22127011
114. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure. Nathwani N, Krishnan AY, Huang Q, Kim Y, Karanes C, Smith EP, Forman SJ, Sievers E, Thomas SH, Chen RW, Leuk Lymphoma 2012 http://www.ncbi.nlm.nih.gov/pubmed/22369501
115. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC, Clin Cancer Res 2010 16 3 888 897 10.1158/1078-0432. CCR-09-2069 20086002
116. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A, N Engl J Med 2010 363 19 1812 1821 10.1056/NEJMoa1002965 21047225